Table 2.

Olaratumab-related treatment-emergent adverse events across all cycles^†,‡

	Number of patients, n (%)
Preferred term	Cohort 1 (10 mg/kg) n = 3	Cohort 2 (20 mg/kg) n = 7	Cohort 3 (15 mg/kg) n = 6
Patients with any AE	1 (33.3)	6 (85.7)	1 (16.7)
Hematologic
Anemia	0	1 (14.3)	0
Leukopenia	0	1 (14.3)	0
Non-hematologic
Aspartate aminotransferase increased	0	2 (28.6)	0
Cough	1 (33.3)	0	0
Dermatitis	0	0	1 (16.7)
Diarrhea	0	1 (14.3)	0
Fatigue	0	1 (14.3)	0
Fibrin D-dimer increased	0	1 (14.3)	0
Hyperglycemia	0	1 (14.3)	0
Hypertension	0	1 (14.3)	0
Proteinuria	0	3 (42.9)	1 (16.7)
Rash	0	1 (14.3)	0
Tumor hemorrhage	0	1 (14.3)	0

^†For each preferred term, each patient is counted only once per preferred term.

^‡AEs with missing relationship to study drug were considered as related. AE, adverse event.